A WRDA has not been authorized since 2007. A new authorization is necessary to continue approved flood control.
In your testimony you note that we have a statutory directive that exists under current law that all patents are to be p...
Pharmaceutical patents are extremely valuable and it's for good reason that they're valuable.
Opponents of reverse settlements have for several years argued that they're anti-competitive.
Both this recoupment of investment and these profits are jeopardized by lawsuits that are filed by generics.
Proponents of the agreements have argued that the agreements can never properly be considered anti-competitive.
I agree with the holding of the Supreme Court.
But to assume that requires us to assume at the outset that the patent is, in fact, invalid.
On average, it takes 10 years and $1 billion to develop and gain FDA approval for a new drug.
I want to talk just a little bit about our use of the term 'pay for delay' today.
Wouldn't you have to concede that then in that circumstance you've got pro-competitive effects?